INTRODUCTION
GB virus type A (GBV-A) and type C (GBV-C, also called hepatitis G virus) were discovered in 1995, and a closely related chimpanzee variant (GBV-Ccpz) was identified in 1998 (Adams et al., 1998; Birkenmeyer et al., 1998; Simons et al., 1995) . GBV-A, GBV-C and a bat GB virus (GBV-D) were recently assigned to a novel genus Pegivirus within the family Flaviviridae by the executive committee of the International Committee on the Taxonomy of Viruses (ICTV) ICTV, 2012) . Although GBV-C was initially thought to cause hepatitis, epidemiological studies failed to identify an association between human GBV-C infection and acute or chronic hepatitis in humans or chimpanzees (Alter, 1997; Polgreen et al., 2003; Stapleton, 2003) . GBV-C is lymphotropic, and the virus is found in and produced by T-and B-lymphocytes obtained from infected individuals (Fogeda et al., 1999; George et al., 2003 George et al., , 2006 Rydze et al., 2012; Xiang et al., 2000) . The cellular tropism of GBV-A and GBV-Ccpz has not been elucidated (reviewed by Stapleton et al., 2011) . Due to shared modes of transmission, the prevalence of GBV-C in human immunodeficiency virus type 1 (HIV-1)-infected people is high (17-42 %) (Rey et al., 2000; Tillmann et al., 2001; Xiang et al., 2001) . Several, though not all studies observed a beneficial association between GBV-C infection and improved survival in HIV-infected individuals (reviewed by Mohr & Stapleton, 2009; Polgreen et al., 2003; Stapleton, 2003) . Evidence supporting several potential mechanisms by which GBV-C may influence HIV disease progression have been identified, including direct antiviral effects, altered expression of cytokines, chemokines, HIV entry receptors and modulation of host cell signalling pathways (Bhattarai & Stapleton, 2012a; Bhattarai et al., 2012b; Mohr & Stapleton, 2009 ).
The GBV-C envelope glycoprotein E2 inhibits HIV-1 replication when it is added to or is expressed within primary or transformed CD4
+ T-cells (Jung et al., 2007; Xiang et al., 2012) . Similarly, a 17 aa region within the GBV-C E2 protein is sufficient to potently inhibit HIV-1 when delivered to, or expressed within CD4
+ T-cells (Xiang et al., 2012) . Because this 17mer E2 peptide is part of a larger peptide previously shown to form an amphipathic helix in the presence of lipids and model membranes, it is thought that this region may be involved in GBV-C fusion to host cell membranes (Larios et al., 2005) . Another E2 peptide that overlaps with the putative fusion peptide prevents oligomerization of the HIV-1 gp41 membrane proximal ectodomain (MPER) and thus inhibits HIV-1-membrane fusion in an in vitro model (Herrera et al., 2009) . These findings raise the possibility of structural or functional mimicry between the putative GBV-C fusion domain and the HIV-1 fusion domain.
Although chimpanzees are permissive for HIV (Fultz et al., 1986) and human GBV-C infection (Bukh et al., 1998) , no animal models of GBV-C co-infection with HIV are described. In addition, there are no published reports of in vitro or in vivo interactions between the GBV-Ccpz variant and HIV. Among captive chimpanzees, the prevalence and persistence rates of GBV-Ccpz infection are similar to GBV-C infection in humans, with a low but detectable prevalence of persistent viraemia and a higher prevalence of antibody to GBV-C E2 protein indicating prior infection (Mohr et al., 2011) . Only one full-length sequence of GBV-Ccpz is published, and this sequence and the E2 protein coding region share 69 % amino acid identity with human GBV-C isolates (Birkenmeyer et al., 1998; Stapleton et al., 2011) . There are no published data that characterize the GBV-Ccpz E2 protein or that examine the potential of GBV-Ccpz or GBV-A E2 protein interactions with HIV. However, if the HIV inhibitory effect of human GBV-C E2 protein is shared with GBV-Ccpz or with the New World primate virus GBV-A, two potential animal models of the interaction between members of the genus Pegivirus and HIV would be possible. Here, we characterize GBV-Ccpz E2 coding sequences from isolates from two infected chimpanzees, and express one of these in a CD4
+ T-cell line. HIV-1 replication was inhibited in cells expressing GBV-Ccpz E2 protein, the GBV-Ccpz and the GBV-A 17mer peptides homologous to the human GBV-C 17mer peptide previously shown to inhibit HIV-1 in vitro. The E2 protein and peptide inhibit HIV replication by reducing HIV entry into the cells, and this is independent of HIV receptor expression.
RESULTS
Characterization of the GBV-Ccpz E2 protein coding region
The GBV-Ccpz genome region that aligns to the human predicted GBV-C E2 protein coding region (nt 1167-2318 based on the infectious GBV-C clone, GenBank accession no. AF121950) was amplified from chimpanzee serum using two sets of overlapping primers (see Methods) in nested RT-PCRs as described previously (Xiang et al., 2000) . The resultant amplicons were cloned and sequenced as described before (Xiang et al., 2006) , and the two newly described GBV-Ccpz E2 nucleotide and deduced amino acid sequences submitted to GenBank (accession nos JX472278 and JX472279 from animals 1855 and Candi, respectively). Phylogenetic analysis of the predicted GBVCcpz E2 coding region demonstrated that they were more closely related to the published GBV-Ccpz E2 region than to human GBV-C isolates. Specifically, the E2 coding region of the two isolates differed from each other by only 2 % (nucleotide; Fig. 1a) , and 1 % (amino acid; Fig. 1b) , or from the published GBV-Ccpz sequence (AF070476) by 10 and 3 %, respectively. In contrast, there was greater divergence between the GBV-Ccpz E2 coding regions and the human GBV-C E2 coding region, with a mean of 37 % nt and 31 % aa difference, respectively. The deduced GBVCcpz E2 protein was 375 aa in length and compared with the human GBV-C E2 protein, all three predicted GBVCcpz E2 proteins lacked 6 aa at the extreme C terminus. Despite this truncation, the predicted signal peptidase cleavage site was maintained in both the human and the chimpanzee GBV-C E2 proteins (Fig. 1c) . All three GBVCcpz E2 proteins were predicted to have three glycosylation sites at amino acid positions 37 (N-linked), 105 (N-linked) and 240 (O-linked) (Blom et al., 2004) .
GBV-Ccpz E2 protein expression inhibits HIV replication
Expression of the human GBV-C E2 protein in Jurkat cells potently inhibits HIV replication (Xiang et al., 2012) . Since there is 31 % difference in amino acid identity between the human and chimpanzee GBV-C virus isolates, it was unclear if the GBV-Ccpz E2 protein would inhibit HIV replication as well. Consequently, the GBV-Ccpz C E2 protein with a C-terminus truncation to remove the transmembrane domain was ligated into a previously described tet-repressible, bicistronic vector (Xiang et al., 2006) . The resulting plasmid encoded GBV-Ccpz aa 1-331. The plasmid contains a Kozak sequence directing translation of the GBV-Ccpz E2 reading frame of the JX472278 sequence containing an in-frame polyhistidine tag, followed by stop codons in all three reading frames, and the encephalomyocarditis virus internal ribosomal entry site which directs translation of GFP. Tet-off Jurkat cells were transfected with this plasmid, and a bulk cell line was selected by growing cells in hygromycin and neomycin and sorting for GFP-positive cells using FACS as previously described (Xiang et al., 2006) . Previously described Jurkat cell lines that expressed the vector control (with GFP), or the human GBV-C E2 protein coding region in which a frameshift was introduced (FS) to abolish protein expression served as the negative controls, and a Jurkat cell line that expressed E2 protein amplified from a human GBV-C isolate served as the positive control (Xiang et al., 2012) .
GBV-Ccpz E2 with C-terminal his-tag expression was demonstrated in GFP-positive cells by immunoblot analysis using mouse polyclonal anti-GBV-C E2 sera, and an anti-His mAb (Fig. 2a) . GBV-Ccpz E2 was not detected using the anti-peptide rabbit sera, consistent with the fact that there were three amino acid differences between the chimpanzee GBV-C peptide sequence and the human E2 peptide sequence for rabbit immunization. Both GBV-C E2 and GFP expression were diminished by growing cells in doxycycline (1 mg ml
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) for 5 days, as measured by immunoblot and flow cytometry (Fig. 2) .
HIV replication was not detected following infection of Jurkat cells expressing either the chimpanzee GBV-C E2 or the human GBV-C E2 proteins with a clade B, clinical, X4-tropic HIV isolate [catalogue number 1073, NIH AIDS Research and Reference Reagent Program (NARRRP); Fig.  3a ]. This anti-HIV replication effect of E2 protein was reversed by maintaining cells in doxycycline to reduce E2 expression (data represent HIV p24 antigen released into culture supernatants from three independent cultures; Fig. 3a) . The individual cultures from three independent infections obtained 7 days post-infection (p.i.) were tested, and HIV replication was significantly higher in the FS control cells compared with Jurkat cells expressing either the human or chimpanzee GBV-C E2 proteins, even when maintained in doxycycline (P,0.001; Fig. 3a ). Nevertheless, HIV replication was significantly higher in the Jurkat cells expressing GBV-C E2 proteins maintained in doxycycline compared with those without doxycycline (P,0.001), indicating that HIV inhibition correlated with human and chimpanzee GBV-C E2 expression levels. As previously described for the human GBV-C E2 protein-expressing Jurkat cells, there were no differences in cell viability as measured by trypan blue exclusion microscopy (data not shown).
Single cycle replication assays allow assessment of viral envelope specificity, and provide information regarding which step(s) of HIV-1 replication is inhibited. HIV gp160 envelope pseudotyped HIV particles (HIVpp) or vesicular stomatitis virus envelope glycoprotein (VSVG) pseudotyped HIV particles (VSVGpp) containing a luciferase reporter gene were generated in 293T cells as previously described (Mohr et al., 2010; Xiang et al., 2008) . The Jurkat cell lines expressing human and chimpanzee GBV-C E2 protein or the FS control were transduced with the HIVpp and VSVGpp, and luciferase activity was measured 96 h later. Consistent with the replication competent studies shown in Fig. 3(a) , both human-and chimpanzee-derived GBV-C E2 protein expression inhibited HIVpp transduction in Jurkat cells (P,0.001 compared with the FS control; Fig. 3b ). Transduction inhibition was significantly reduced by maintaining the cells in doxycycline. In contrast, there were no significant differences in VSVGpp transduction in the Jurkat cells expressing GBV-C E2 proteins compared to transduction in the FS control Jurkat cells (Fig. 3c) . Furthermore, maintaining the cells in doxycycline did not alter VSVGpp transduction. Since Fig. 1 . Phylogenetic relationships between human and chimpanzee GBV-C E2 protein coding regions. The nucleotide (nt) (a) and deduced amino acid (aa) (b) sequences of the predicted GBV-C E2 coding region to the predicted signal peptidase cleavage site at the C terminus of E2 and the N terminus of the putative P7 protein (nt 1167-2318 based on GenBank accession no. AF121950) of representative isolates of the seven human genotypes (GT) and the three chimpanzee isolates (cpz; GenBank accession nos JX472278, JX472279 and AF070476 for GBV-Ccpz 1855, GBVCcpz Candi and the published complete GBV-Ccpz genome, respectively) are shown. (c) Despite a 6 aa deletion at the C terminus of the predicted GBV-Ccpz E2 protein, the predicted signal peptidase site is retained in the GBV-Ccpz deduced amino acid sequence. Bars, 0.05 nucleotide (a) or amino acid (b) substitutions per site.
HIVpp, but not VSVGpp transduction was inhibited by human and chimpanzee GBV-C E2 protein expression and these particles used the same defective retrovirus backbone, the inhibitory effect is related at least in part to HIVenvrelated entry, although post-entry steps might also be inhibited. GBV-C E2 from chimpanzees or humans did not change the surface expression of HIV receptors (CD4, CCR5 and CXCR4) on Jurkat cells by flow cytometry (data not shown), thus HIV entry inhibition was not due to altered receptor expression. The extent of HIV inhibition in the single cycle assay was less than that observed in the infection model (Fig. 3) , suggesting that expression of E2 in CD4
+ cells effectively prevents cell-cell spread, or that another step besides HIV entry is inhibited by GBV-C E2 expression.
To determine if expression of the chimpanzee GBV-C E2 protein in Jurkat cells inhibits diverse HIV isolates, five additional HIV isolates were studied. Table 1 provides a summary of the characteristics of the viruses studied. These HIV isolates represent both clinical and laboratory derived strains, and include HIV from clades A, B and D. Since GBV-C E2 protein elicits antibodies that cross-react with HIV particles (Mohr et al., 2010) , and HIV gp41 T-20 peptide (Fuzeon) react with broadly reactive HIV neutralizing antibodies, it is possible that molecular mimicry between GBV-C and HIV-1 gp41 plays a role in HIV-1 inhibition. To test this hypothesis, two of the HIV isolates studied were resistant to T-20 (Table 1) . T-20-resistant viruses were generated by transfecting 293T cells with infectious molecular clones as previously described (Xiang et al., 2012) . All HIV isolates examined, including the T-20-resistant HIV strains, were inhibited in Jurkat cells expressing GBV-Ccpz E2 and GBV-Chum E2 as compared with the FS control ( Fig. 4 ; P,0.001 for all).
GBV-Ccpz and GBV-A E2 peptides are sufficient to inhibit HIV replication
We previously reported that expression of the human GBV-C E2 protein or a peptide motif within E2 (aa 276-292) in CD4 + Jurkat cells significantly inhibited HIV replication in those cells. Furthermore, HIV replication in a CD4 + T-cell line or in primary CD4 + T-cells was inhibited by the addition of a synthetic peptide representing the 276-292 peptide motif (Xiang et al., 2012) . Alignment of the three GBV-Ccpz E2 and the GBV-A (GenBank accession no. AF023424) E2 sequences identified homology between the human and chimpanzee GBV-C E2 peptide region, and to a much lesser extent, the GBV-A peptide region. There were two conserved amino acid differences and two additional amino acid polymorphisms in this region in the chimpanzee GBV-C E2 coding region. However, there were ten amino acid differences in the GBV-A coding region (Fig. 5a) . Expression of the 17mer GBV-C E2 peptide from both the human and the chimpanzee isolates rendered the Jurkat cells unable to support HIV replication, while Jurkat cells containing the human 17mer amino acids in a scrambled order did not inhibit HIV when compared with HIV replication in the frameshift control cells (Fig. 5b) . Expression of the GBV-A 17mer peptide also significantly inhibited HIV replication; however, to a lesser extent than either GBV-C sequence (Fig. 5b) . These data suggest that there are critical residues within this peptide motif required for HIV inhibition, and studies to characterize the amino acid required are under way. Neither the GBV-Ccpz or GBV-A 17mer peptides altered cell viability based on trypan blue exclusion microscopy (data not shown). Similar to the near-full-length E2 protein expression, HIVpp were inhibited by the GBVCcpz E2 17mer peptide while VSVGpp were not (Fig. 5c,   d ). Thus, this peptide sequence from human and chimpanzee GBV-C and GBV-A E2 proteins are sufficient to inhibit HIV replication, and the inhibition involves HIV entry into cells. Although GBV-C is associated with reduced surface expression of HIV entry coreceptors CD4, CCR5 and CXCR4 (Maidana Giret et al., 2009; Nattermann et al., 2003; Schwarze-Zander et al., 2010; Xiang et al., 2004 Xiang et al., , 2006 Xiang et al., , 2009 , none of these receptors were reduced on the surface of Jurkat cells expressing GBV-C E2 proteins or the GBV-A peptide compared to the control cell lines (data not shown). Thus, the HIV entry inhibition is not due to altered HIV entry receptor expression, and studies to further characterize the mechanism of interference are under way. Table 1 ). HIV inhibition rates are represented as a percentage of the reduction of HIV p24 antigen compared with FS. *, Inhibition was significantly less than other isolates (P,0.001) except isolate B-T2.
GBV-Ccpz E2-expressing cells inhibit HIV-1 replication in bystander cells
Since GBV-C is estimated to infect a small number of CD4 + T-cells in infected humans (,5 %) (Xiang et al., 2000; Rydze et al., 2012; Bhattarai & Stapleton, 2012a) , expression of E2 protein in cells may not lead to an effect in vivo. To determine if GBV-Ccpz E2 inhibits HIV-1 replication in bystander cells, MT-2 cells were infected with or without co-cultivation (1 : 1 ratio) with GBV-Ccpz E2-expressing Jurkat cells or control cells including parental Jurkat, FS and GBV-Ccpz E2 maintained in doxycycline. GBV-Ccpz E2 significantly reduced HIV replication in MT-2 cells, and this was significantly reduced in GBV-Ccpz E2-expressing cells maintained in doxycycline to reduce E2 expression (P,0.001 for all comparisons; Fig. 6 ). In contrast, incubation of parental Jurkat cell controls or the GBV-C E2 frameshift (FS) control did not inhibit HIV replication in MT-2 cells. Inhibition was not observed when the GBV-Ccpz E2 Jurkat cells were separated from direct contact with the MT-2 cells in transwells, indicating that cell-to-cell communication may be required for E2 to inhibit HIV replication in bystander cells. Studies to characterize this mechanism are under way.
DISCUSSION
The natural history and prevalence of chimpanzee GBVCcpz in captive chimpanzees is similar to that observed for human GBV-C infection in healthy blood donors (Mohr et al., 2011) ; however, no experimental data exist characterizing chimpanzee GBV-C or the GBV-Ccpz E2 protein. The two newly reported GBV-Ccpz E2 deduced amino acid sequences differ from the single published GBV-Ccpz E2 by roughly the same amount as do the E2 amino acid sequences of different human GBV-C genotypes (Fig. 1) . However, deduced GBV-Ccpz E2 amino acids differ by 31 % from human GBV-C sequences. Despite this sequence heterogeneity, GBV-Ccpz E2 retains the in vitro HIV inhibitory phenotype observed for human GBV-C E2 protein (Xiang et al., 2012) . Interestingly, there is a 6 aa deletion at the putative C terminus of the GBV-Ccpz E2, yet the predicted signal peptidase cleavage site was retained.
Like GBV-C E2, GBV-Ccpz E2 inhibited diverse HIV isolates in both replication-competent and single-cycle infections. Expression of the previously mapped GBV-C E2 17mer peptide as well as the homologous peptide regions of GBV-Ccpz and GBV-A E2 were sufficient to inhibit HIV replication, despite considerable amino acid differences in the peptide sequences (Fig. 5a ). For the human GBV-C E2 protein, this region was shown to be part of a peptide that forms an amphipathic helix in the presence of lipids, suggesting a role in GBV-C cell fusion (Larios et al., 2005) . It is tempting to speculate that the GBV-C and GBV-A E2 peptides interfere with HIV entry via competition with HIV-cell fusion, and studies are under way to address this hypothesis.
A limitation of our data is that we removed the C-terminal transmembrane domain of both human and chimpanzee GBV-C E2 protein in our studies. Due to cellular toxicity, we were unable to express the full-length protein in Jurkat cells, even using a tet-on system (data not shown). Nevertheless, taken together, the finding that expression of human and chimpanzee GBV-C E2 protein and the peptide motif of GBV-C, GBV-Ccpz and GBV-A in a CD4 + T-cell line inhibited HIV replication and that the addition of recombinant human GBV-C E2 (Jung et al., 2007) or the synthetic peptide motif to CD4
+ T-cells inhibits HIV entry (Xiang et al., 2012) supports the hypothesis that GBV-C E2 protein contributes to the inverse relationship between GBV-C and HIV viral loads observed in human clinical trials (Tillmann et al. 2001; Björkman et al. 2007) , and to the beneficial association between GBV-C and survival in HIV-infected humans (reviewed by Mohr & Stapleton, 2009 ).
GBV-C appears to infect a small proportion of human Band T-lymphocytes (George et al., 2006) ; however, no data exist on GBV-Ccpz or GBV-A tropism in vivo. Nevertheless, the finding that GBV-Ccpz E2-expressing cells can reduce infection in bystander MT-2 cells suggests that the HIV inhibitory effect may extend more broadly than infected cells. Furthermore, the mean chimpanzee GBV-Ccpz viral load is greater than 1610 8 genome copies ml
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, similar to what is observed for GBV-C infection of humans (Mohr et al., 2011; Rydze et al., 2012) . Given that E2 is thought to be part of the virion, a relatively high concentration of the GBV-Ccpz E2 protein is in contact with CD4
+ T-cells in vivo. Although the recent ban on chimpanzee research in the USA and Western Europe makes the development of a GBVCcpz-HIV model unlikely in developed nations (NIH Webpage, 2012) , the data showing that the GBV-A E2 peptide domain also inhibits HIV replication raises the possibility of using GBV-A infection of New World primates as an animal model to examine Pegivirus-SHIV (chimeric simian immunodeficiency virus/HIV-1 virus) interactions. In addition, understanding the structural basis of the GBV-C E2 peptide inhibition of HIV entry may provide novel approaches to inhibiting HIV entry.
METHODS
Characterization of the GBV-Ccpz E2 coding sequence. Serum samples from two chimpanzees previously shown to be chronically infected with GBV-C (Mohr et al., 2011) were obtained at the Texas Biomedical Research Institute in San Antonio, TX. RNA was extracted by Qiagen Mini RNAeasy kit (Qiagen) for RT-PCR and sequence analysis was carried out as previously described (Xiang et al., 2000) . The GBV-Ccpz genome region containing the sequence that aligned with the putative complete human GBV-C E2 coding region (1167-2178 based on GenBank accession no. AF121950) was amplified by first generating cDNA with the antisense primer (59-GCACCGCCTCAGTCACTG-39; AF121950 nt 5332-5349 based on AF121950; Invitrogen cDNA synthesis kit) followed by nested PCR amplification of two overlapping genome regions. For the upstream amplicon, the following primers were used: outer sense 59-TACTGGATACTGGAGTATCT-39; outer antisense 59-CTCGGTGGTCGACGATCCA-39; inner sense 59-TGGCGCCTT-CCCTTTGACT-39; inner antisense 59-CTAGGACCGCTATGGTGCA-39. For the downstream amplicon, the following primers were utilized: outer sense: 59-AGTCAAAGGGAAGGCGCCA-39; outer antisense 59-CAGAAGTACGCAGCCAAGCACCA-39; inner sense 59-AGATACTC-CAGTATCCAGTA-39; inner antisense 59-GTCTCCATCCACCAGC-GCTCAT-39. These amplicons were ligated into pCR2.1 and sequenced by the University of Iowa DNA Core Facility using ABI automated sequencing as described previously (Xiang et al., 2006) . Subsequently, the putative GBV-Ccpz E2 coding region truncated at the C terminus to remove the predicted transmembrane domain was amplified using the same cDNA as above followed by nested RT-PCR using the following primers: outer and inner sense primer: 59-AGGATCCCATGGGAC-CCTTTGTCCCCGGTC-39, outer antisense 59-ATGCGGCCGCCAAA-GGCGCTGCAAAT-39, and inner antisenses 59-AGCGGCCGCCCA-TGAATGGTCGTCGA-39. For expressing GBV-Ccpz or GBV-A E2 peptide sequences, synthetic oligonucleotides were purchased (Iowa DNA Technologies) and ligated into the modified pTRE2 vector as previously described for other peptide sequences (Xiang et al., 2006) . E2 sequences from GBV-C isolates obtained from humans and chimpanzees were aligned with published sequences using the CLUSTAL W method and evolutionary histories were inferred using the UPGMA method and evolutionary distances were computed using the Maximum Composite Likelihood method using DNAman software (Linnen, Biosoft). The two newly described GBV-Ccpz E2 nucleotide and deduced amino acid sequences (from animals 1855 and Candi; GenBank accession nos JX472278 and JX472279, respectively) were analysed in comparison with the only published GBV-Ccpz E2 sequence (GenBank accession no. AF070476), and representative GBV-C isolates from each human GBV-C genotype (GT): GT 1, GenBank accession no. AB003291; GT 2, AF121950; GT 3, U94695; GT 4, AB018667; GT 5, AY949771; GT 6, AB003292; and GT 7, KY117.
Stable transfection of GBV-C E2 protein and controls in Jurkat cells. GBV-Ccpz E2 protein from chimpanzee 1855 (GenBank accession no. JX472278) or the 17mer GBV-Ccpz and GBV-A (GenBank accession no. AF023424) E2 peptides were inserted into a modified Tet-off pTRE2-HGY plasmid (Clontech) as previously described (Xiang et al., 2006) . This vector has a Kozak sequence, an Ig-kappa secretory leader sequence at the N terminus and a polyhistidine tag in-frame at the C terminus of the E2 insert, followed by stop codons in all three reading frames, and the EMCV IRES which directs translation of GFP. The negative controls included an empty vector control (which expresses GFP) and the human GBV-C E2 sequence in which a frameshift mutation was inserted to prevent translation of the E2 protein (FS) as described previously (Xiang et al., 2006) . Tet-off Jurkat cells (Clontech) were transfected with the GBV-Ccpz E2 plasmids and the control plasmid by Amaxa nucleofection (Lonza). Cells were selected in hygromycin and neomycin G418 (200 mg ml 21 each) medium for 3-4 weeks, and GFP-positive cells were bulk-sorted by FACS (Diva flow selection, University of Iowa Microscopy Core Facility). Chimpanzee and human GBV-C E2 protein expression in Jurkat cells was determined by SDS-PAGE, immunoblot analysis using an anti-His mAb (Penta-His; Qiagen), mouse polyclonal anti-GBV-C E2 serum or rabbit anti-human GBV-C E2 peptide serum as described by Mohr et al. (2010) . For the hygromycin-resistant, GFP-positive cell line expressing the GBV-Ccpz 17mer peptide or the control peptide sequence, total cellular RNA was extracted from cells and the peptide sequence was confirmed by RT-PCR and sequence analysis as above.
HIV infection or transduction. Four strains of HIV CXCR4-tropic (X4 strain) representing clades A, B and D, and two T-20 drugresistant isolates (T-20) were studied. All were provided by the NIH AIDS Research and Reference Reagent Program (NARRRP) and characteristics are summarized in Table 1 (Mohr et al., 2010) . For all infections, 10 ng HIV was applied to 1610 6 cells in 24-well culture plates for 3 h at 37 uC, cells were washed three times and maintained in RPMI growth medium (10 % FCS, 1 % penicillin/streptomycin and 1 % glutamine; Gibco) for up to 7 days. Cell culture supernatants were harvested at the indicated times and replication determined by measuring p24 antigen by ELISA. HIV-1 replication was determined by measuring HIV-1 p24 antigen in culture supernatants (Retro-Tek HIV-1 p24 antigen ELISA kits; Zeptometrix). All infections were performed in triplicate and data represent the mean p24 antigen release into the supernatants from the three infections. All triplicate experiments were repeated at least once with consistent results.
Pseudotyped viruses transduction. Pseudotyped HIV particles were generated in 293T cells using pNL4-3-Luc.R-E-(NIRRRP catalogue number 3417) and either HIV envelope (pHXB2env; NIRRRP catalogue number 1069) or vesicular stomatitis virus glycoprotein (VSVG) envelope (pHEF-VSVG; NIRRRP catalogue number 4693). Jurkat cells (8610 4 cells per well) were transduced with the HIV-pseudotyped or VSVG control particles (normalized by HIV p24 antigen content), and luciferase activity was assessed 96 h post-transduction as recommended by the manufacturer using a Luminometer (Promega). As with infections, all transductions were performed in triplicate and all experiments were repeated at least once with consistent results.
HIV entry receptor detection. Jurkat cells that stably expressed GBV-C E2 sequences or control Jurkat cells were incubated at 4 uC for 30 min with mouse anti-CD4 (PE-conjugated) or anti-CXCR4 (PE-conjugated) mAbs (BD Pharmingen), followed by washing with PBS. Cell-surface CD4 and CXCR4 levels were determined by flow cytometry (FACScan; Becton Dickinson) as previously described (Xiang et al., 2001) .
Sequences analysis and statistics. Sequence analysis was performed using DNAman (Linnen, Biosoft) and MEGA. Statistics were performed using SigmaStat software V2.03S (Jandel Scientific) and Graphpad Prism (GraphPad version 4.03 software). Comparisons of two samples utilized a Student's t-test, and comparisons of more than three samples utilized ANOVA.
